FR23C1052I1 - 2'-fluoro-2'-desoxytetrahydrouridines comme inhibiteurs de cytidine desaminase - Google Patents

2'-fluoro-2'-desoxytetrahydrouridines comme inhibiteurs de cytidine desaminase

Info

Publication number: FR23C1052I1
Authority: FR; France
Prior art keywords: desoxytetrahydrouridines; desaminase; cytidine; fluoro; inhibitors
Prior art date: 2007-10-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR23C1052C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Otsuka Pharmaceutical Co Ltd

Original Assignee

Otsuka Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-16

Filing date

2023-12-26

Publication date

2024-01-26

2023-12-26 Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd

2024-01-26 Publication of FR23C1052I1 publication Critical patent/FR23C1052I1/fr

Status Active legal-status Critical Current

Links

UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 title 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 title 1
UHDGCWIWMRVCDJ-XVFCMESISA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-XVFCMESISA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FR23C1052C 2007-10-16 2023-12-26 2'-fluoro-2'-desoxytetrahydrouridines comme inhibiteurs de cytidine desaminase Active FR23C1052I1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98039707P	2007-10-16	2007-10-16
PCT/US2008/080163 WO2009052287A1 (fr)	2007-10-16	2008-10-16	Certains composés, compositions et procédés

Publications (1)

Publication Number	Publication Date
FR23C1052I1 true FR23C1052I1 (fr)	2024-01-26

Family

ID=40251685

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FR23C1052C Active FR23C1052I1 (fr)	2007-10-16	2023-12-26	2'-fluoro-2'-desoxytetrahydrouridines comme inhibiteurs de cytidine desaminase
FR23C1051C Active FR23C1051I1 (fr)	2007-10-16	2023-12-26	2'-fluoro-2'-desoxytetrahydrouridines comme inhibiteurs de cytidine desaminase

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
FR23C1051C Active FR23C1051I1 (fr)	2007-10-16	2023-12-26	2'-fluoro-2'-desoxytetrahydrouridines comme inhibiteurs de cytidine desaminase

Country Status (39)

Country	Link
US (4)	US8268800B2 (fr)
EP (2)	EP2447272B1 (fr)
JP (2)	JP5496899B2 (fr)
KR (1)	KR101543049B1 (fr)
CN (1)	CN101827856B (fr)
AT (1)	ATE548374T1 (fr)
BR (1)	BRPI0818672B8 (fr)
CA (1)	CA2702274C (fr)
CO (1)	CO6270330A2 (fr)
CR (1)	CR11427A (fr)
CY (3)	CY1112781T1 (fr)
DK (1)	DK2207786T3 (fr)
EA (1)	EA018757B1 (fr)
EC (1)	ECSP10010095A (fr)
ES (2)	ES2384011T3 (fr)
FI (2)	FIC20230040I1 (fr)
FR (2)	FR23C1052I1 (fr)
GT (1)	GT201000088A (fr)
HK (1)	HK1146410A1 (fr)
HR (1)	HRP20120419T1 (fr)
HU (2)	HUS2300045I1 (fr)
IL (1)	IL204732A (fr)
JO (1)	JO2778B1 (fr)
ME (1)	ME00997B (fr)
MX (1)	MX2010004109A (fr)
MY (1)	MY147970A (fr)
NI (1)	NI201000055A (fr)
NL (1)	NL301256I2 (fr)
NO (2)	NO2023047I1 (fr)
NZ (1)	NZ584229A (fr)
PL (1)	PL2207786T3 (fr)
PT (1)	PT2207786E (fr)
RS (1)	RS52323B (fr)
SA (1)	SA08290661B1 (fr)
SI (1)	SI2207786T1 (fr)
TW (1)	TWI445539B (fr)
UA (1)	UA99476C2 (fr)
WO (1)	WO2009052287A1 (fr)
ZA (1)	ZA201002178B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain vehicles, installations and methods
HUE064677T2 (hu)	2008-05-15	2024-04-28	Celgene Corp	Citidin-analógokat tartalmazó orális készítmények és eljárások azok alkalmazására
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US20100055047A1 (en) *	2008-08-26	2010-03-04	Yiyu Zou	Methods for treating bronchial premalignancy and lung cancer
CL2009002206A1 (es) *	2008-12-23	2011-08-26	Gilead Pharmasset Llc	Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
US8329665B2 (en)	2009-04-06	2012-12-11	Eisai Inc.	Compositions and methods for treating cancer
JP5687687B2 (ja)	2009-04-06	2015-03-18	大塚製薬株式会社	癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
ES2628580T3 (es) *	2009-04-06	2017-08-03	Otsuka Pharmaceutical Co., Ltd.	Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer
GB0907551D0 (en)	2009-05-01	2009-06-10	Univ Dundee	Treatment or prophylaxis of proliferative conditions
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
PE20130151A1 (es)	2010-03-31	2013-02-21	Gilead Pharmasset Llc	Sintesis estereoselectiva de activos que contienen fosforo
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
TW201242974A (en)	2010-11-30	2012-11-01	Gilead Pharmasset Llc	Compounds
MD4589C1 (ro)	2011-09-16	2019-03-31	Gilead Pharmasset Llc	Compoziţie farmaceutică cu conţinut de sofosbuvir şi utilizarea acesteia în tratamentul hepatitei virale C
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
EA029081B9 (ru)	2013-01-31	2018-09-28	Джилид Фармассет Ллс	Комбинированный состав двух противовирусных соединений
CA2921160C (fr)	2013-08-27	2021-04-13	Gilead Pharmasset Llc	Preparation combinee de deux composes antiviraux
AU2014342402B2 (en)	2013-10-29	2018-11-01	Otsuka Pharmaceutical Co., Ltd.	Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
MX2016013027A (es)	2014-04-04	2017-05-23	Del Mar Pharmaceuticals	Uso de dianhidrogalactitol y analogos o derivados del mismo para tratar cancer de celulas no pequeñas del pulmon y cancer de ovario.
EP3925609A1 (fr)	2014-08-22	2021-12-22	Celgene Corporation	Méthodes de traitement du myélome multiple avec des composés immunomodulateurs en combinaison avec des anticorps
EP3960182A1 (fr) *	2015-12-03	2022-03-02	Epidestiny, Inc.	Compositions contenant de la décitabine, de la 5-azacytidine et de la tétrahydrouridine et leurs utilisations
WO2017158396A1 (fr)	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibiteurs de cytidine désaminase pour le traitement du cancer du pancréas
PE20210367A1 (es)	2018-02-02	2021-02-26	Maverix Oncology Inc	Conjugados de farmacos de molecula pequena de monofosfato de gemcitabina
US11224610B2 (en) *	2018-09-19	2022-01-18	Otsuka Pharmaceutical Co., Ltd.	Low dose combination CDA substrate drug/cedazuridine with extended administration
US20210388361A1 (en) *	2018-10-19	2021-12-16	Interoligo Corporation	Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
CN112888700A (zh) *	2018-10-19	2021-06-01	因特欧力多公司	具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
JP2022552817A (ja) *	2019-10-08	2022-12-20	大塚製薬株式会社	高純度の２’－デオキシ－２’，２’－ジフルオロテトラヒドロウリジン及びその製造方法
CA3163122A1 (fr) *	2020-02-25	2021-09-02	Aram Oganesian	Formes posologiques orales solides a base de deitabine et de cedeuridine
WO2022204126A1 (fr) *	2021-03-26	2022-09-29	The Cleveland Clinic Foundation	Traitement d'une infection par un virus à arn avec un inhibiteur de cytidine désaminase
WO2022254457A1 (fr) *	2021-05-29	2022-12-08	Msn Laboratories Private Limited, R&D Center	Procédé amélioré de préparation de (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxyméthyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one et de ses composés intermédiaires
AU2022370354A1 (en)	2021-10-19	2024-05-30	Akirabio, Inc.	Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (fr) *	2021-11-01	2023-05-04	St. John's University	Composition pharmaceutique liquide injectable contenant de la gemcitabine et un inhibiteur de cytidine désaminase
US20230271996A1 (en) *	2021-12-25	2023-08-31	Scinopharm Taiwan, Ltd.	Process for preparing cedazuridine
WO2024047394A1 (fr)	2022-08-31	2024-03-07	Otsuka Pharmaceutical Co., Ltd.	Polythérapies pour le traitement de lymphomes à lymphocytes t avec tolinapant, cédazuridine et décitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4017606A (en) *	1973-10-04	1977-04-12	The Upjohn Company	Organic compounds and process
US4210638A (en) *	1978-03-17	1980-07-01	Pcr, Inc.	Antiviral composition and method of treating virus diseases
US4275057A (en)	1980-01-28	1981-06-23	The United States Of America As Represented By The Department Of Health, Education And Welfare	Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en)	1983-03-10	1985-07-02	Eli Lilly And Company	Difluoro antivirals and intermediate therefor
JPS61500224A (ja)	1983-10-26	1986-02-06	グリ−ル、シエルダン　ビ−	腫瘍性組織を放射線に対して増感する医薬組成物
DE3587500T2 (de)	1984-12-04	1993-12-16	Lilly Co Eli	Tumorbehandlung bei Säugetieren.
US4965374A (en)	1987-08-28	1990-10-23	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en)	1987-08-28	1993-06-29	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (fr)	1991-04-17	1992-10-29	Yale University	Procede de traitement ou de prevention du virus de l'hepatite b
EP0543976A4 (en)	1991-04-23	1993-11-10	Oglevee, Ltd.	In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr)	1991-10-08	1993-12-10	Commissariat A Energie Atomique	Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en)	1992-06-22	1994-12-06	Eli Lilly And Company	Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en)	1992-06-22	1997-01-14	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5606048A (en)	1992-06-22	1997-02-25	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en)	1992-06-22	1995-06-20	Eli Lilly And Company	Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en)	1992-06-22	1998-10-13	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
WO1994019362A1 (fr)	1993-02-23	1994-09-01	City Of Hope	4-ethoxy 5-fluoro 2'desoxyuridine
WO1994026761A1 (fr) *	1993-05-14	1994-11-24	Pro-Neuron, Inc.	Traitement de la toxicite des agents chimioterapeutiques et des agents antiviraux avec des nucleosides de pyrimidine acyles
GB9311252D0 (en)	1993-06-01	1993-07-21	Hafslund Nycomed As	Cell growth regualtors
US5637688A (en)	1994-12-13	1997-06-10	Eli Lilly And Company	Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en)	1995-01-18	1996-05-28	Eli Lilly And Company	2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
AU5300396A (en) *	1995-03-01	1996-09-18	Human Gene Therapy Research Institute	Radiation enhanced gene therapy for treatment of tumors
US6001994A (en)	1995-12-13	1999-12-14	Eli Lilly And Company	Process for making gemcitabine hydrochloride
US5760208A (en)	1996-08-14	1998-06-02	The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations	Process to prepare pyrimidine nucleosides
EP1156827B1 (fr)	1999-03-01	2006-09-20	Halogenetics, Inc.	USAGE DE COMPOSITIONS COMPRENANT CldC COMME RADIOSENSIBILISATEURS POUR LE TRAITEMENT DE MALADIES NEOPLASTIQUES
US6933287B1 (en)	1999-03-01	2005-08-23	Sheldon B. Greer	Dramatic simplification of a method to treat neoplastic disease by radiation
MXPA02002088A (es)	1999-08-26	2003-09-22	Aortech Internat Plc	Mejoras en relacion al posicionamiento del cateter.
US6462191B1 (en)	2000-07-13	2002-10-08	Air Products And Chemicals, Inc.	Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN102241720B (zh)	2000-11-29	2014-01-29	三井化学株式会社	L-核酸衍生物及其合成方法
ATE290882T1 (de)	2001-01-16	2005-04-15	Glaxo Group Ltd	Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EP2322534A1 (fr)	2001-05-18	2011-05-18	Rakesh Kumar	Nucleosides antiviraux
AU2002322805B2 (en) *	2001-07-31	2007-11-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Inhibitor of DNA methylation
US20040002476A1 (en)	2002-02-14	2004-01-01	Stuyver Lieven J.	Modified fluorinated nucleoside analogues
US6982253B2 (en)	2002-06-05	2006-01-03	Supergen, Inc.	Liquid formulation of decitabine and use of the same
EP1545558A4 (fr)	2002-09-24	2010-02-17	Koronis Pharmaceuticals Inc	1, 3, 5-triazines destinees au traitement de maladies virales
US7265096B2 (en)	2002-11-04	2007-09-04	Xenoport, Inc.	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005115410A2 (fr)	2004-05-06	2005-12-08	University Of Rochester	Inhibiteurs de cytidine-desaminases dependants du contexte et utilisations correspondantes
US20060014949A1 (en)	2004-07-13	2006-01-19	Supergen Inc.	Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (fr)	2004-07-30	2006-02-09	Pharmaessentia Corp.	SYNTHÈSE STÉRÉOSÉLECTIVE DE β-NUCLÉOSIDES
WO2006063105A1 (fr)	2004-12-08	2006-06-15	Sicor Inc.	Difluoronucleosides et procede de preparation de ceux-ci
WO2008085611A2 (fr) *	2006-11-27	2008-07-17	University Of Miami	Concept de thérapie des tumeurs du pancréas
WO2009021551A1 (fr)	2007-08-13	2009-02-19	Universite De La Mediterranee	Procédé d'évaluer du risque de toxicité d'une chimiothérapie
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain vehicles, installations and methods
WO2010047698A1 (fr)	2008-10-22	2010-04-29	University Of Alabama At Birmingham	Répression de maladies auto-immunes par un inhibiteur de la cytidine désaminase induite par activation
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
US8329665B2 (en)	2009-04-06	2012-12-11	Eisai Inc.	Compositions and methods for treating cancer
JP5687687B2 (ja)	2009-04-06	2015-03-18	大塚製薬株式会社	癌を治療するための（２’−デオキシ−リボフラノシル）−１，３，４，７−テトラヒドロ−（１，３）ジアゼピン−２−オン誘導体
ES2628580T3 (es)	2009-04-06	2017-08-03	Otsuka Pharmaceutical Co., Ltd.	Combinación de decitabina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer el tratamiento de cáncer

2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active IP Right Grant
- 2008-10-16 RS RS20120232A patent/RS52323B/en unknown
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/fr active Active
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 CA CA2702274A patent/CA2702274C/fr active Active
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/fr active Application Filing
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 EP EP08840633A patent/EP2207786B1/fr active Active
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/fr unknown
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
2011
- 2011-01-20 HK HK11100565.2A patent/HK1146410A1/xx unknown
2012
- 2012-05-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
2023
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-26 FR FR23C1052C patent/FR23C1052I1/fr active Active
- 2023-12-26 FR FR23C1051C patent/FR23C1051I1/fr active Active
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown

Also Published As

Publication number	Publication date
NZ584229A (en)	2012-06-29
CA2702274A1 (fr)	2009-04-23
ZA201002178B (en)	2011-05-25
NI201000055A (es)	2010-08-13
EP2447272A1 (fr)	2012-05-02
UA99476C2 (en)	2012-08-27
AU2008312435B2 (en)	2014-04-17
DK2207786T3 (da)	2012-06-18
EP2447272B1 (fr)	2017-02-01
GT201000088A (es)	2012-03-13
EP2207786A1 (fr)	2010-07-21
US8268800B2 (en)	2012-09-18
CY2023028I1 (el)	2024-02-16
EP2207786B1 (fr)	2012-03-07
JO2778B1 (en)	2014-03-15
WO2009052287A1 (fr)	2009-04-23
IL204732A (en)	2013-07-31
IL204732A0 (en)	2010-11-30
HUS2300045I1 (hu)	2024-01-28
RS52323B (en)	2012-12-31
BRPI0818672A2 (pt)	2015-04-14
CN101827856B (zh)	2013-02-06
PL2207786T3 (pl)	2012-09-28
TW200924786A (en)	2009-06-16
US20090137521A1 (en)	2009-05-28
JP2011500713A (ja)	2011-01-06
HK1146410A1 (en)	2011-06-03
BRPI0818672B1 (pt)	2020-10-20
HRP20120419T1 (hr)	2012-07-31
KR101543049B1 (ko)	2015-08-07
TWI445539B (zh)	2014-07-21
NO2023048I1 (en)	2023-12-21
CR11427A (es)	2010-08-16
SI2207786T1 (sl)	2012-10-30
ATE548374T1 (de)	2012-03-15
FR23C1051I1 (fr)	2024-01-26
ES2616566T3 (es)	2017-06-13
JP2014177455A (ja)	2014-09-25
PT2207786E (pt)	2012-05-28
AU2008312435A8 (en)	2014-07-24
US9567363B2 (en)	2017-02-14
US20120289475A1 (en)	2012-11-15
ES2384011T3 (es)	2012-06-28
BRPI0818672B8 (pt)	2021-05-25
AU2008312435A1 (en)	2009-04-23
NO2023047I1 (no)	2023-12-21
HUS2300044I1 (hu)	2024-01-28
FIC20230040I1 (fi)	2023-12-22
KR20100091978A (ko)	2010-08-19
CN101827856A (zh)	2010-09-08
SA08290661B1 (ar)	2012-06-10
MY147970A (en)	2013-02-28
ECSP10010095A (es)	2010-07-30
JP5496899B2 (ja)	2014-05-21
US20140186335A1 (en)	2014-07-03
US20150210730A1 (en)	2015-07-30
CA2702274C (fr)	2015-12-29
MX2010004109A (es)	2010-08-10
NL301256I2 (nl)	2024-01-11
ME00997B (fr)	2012-10-20
US8951987B2 (en)	2015-02-10
CY2023029I1 (el)	2024-02-16
JP5859588B2 (ja)	2016-02-10
EA018757B1 (ru)	2013-10-30
EA201000642A1 (ru)	2010-10-29
CY1112781T1 (el)	2016-02-10
US8618075B2 (en)	2013-12-31
FIC20230039I1 (fi)	2023-12-22
CO6270330A2 (es)	2011-04-20
NL301256I1 (fr)	2024-01-03

Publication	Publication Date	Title
FR23C1051I1 (fr)	2024-01-26	2'-fluoro-2'-desoxytetrahydrouridines comme inhibiteurs de cytidine desaminase
BRPI0715344A2 (pt)	2013-11-26	Palmilha de gel
BRPI0815430A2 (pt)	2009-03-05	"quantificação de amamentação"
BRPI0910229A2 (pt)	2015-09-01	Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
BRPI0715313A2 (pt)	2015-04-07	Rastreador solar
BRPI0917773A2 (pt)	2018-02-27	"membro antiviral"
BRPI0810813A2 (pt)	2015-06-16	Agentes anti-hipertensivos de ação dupla
BRPI0718796A2 (pt)	2014-02-18	Nucleotídeo
BRPI0811718A2 (pt)	2014-11-18	Derivados de 3,3-espiroindolinona
FR2916954B1 (fr)	2011-11-25	Agrafe d'osteosynthese
DK2035398T3 (da)	2013-07-08	Immobiliseret 1,2-benzisothioazolin-3-on
DE602007001681D1 (de)	2009-09-03	1,3-dioxan-carboxylsäuren
BRPI0716449A2 (pt)	2013-09-24	disposiÇço de refrigeraÇço
DE602007012247D1 (de)	2011-03-10	Prodrugs von 5-amino-3-(3'-deoxy-beta-d-ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
BRPI0819070A2 (pt)	2014-10-07	"composição energética comestível"
BRPI0810947A2 (pt)	2014-10-14	"composição de condicionamento de cabelos"
BRPI0718141A2 (pt)	2013-11-05	Composições de frangrâncias
BRPI0814725A2 (pt)	2015-08-04	Composição antiviral
BRPI0817136A2 (pt)	2015-03-31	"aba de fixação"
ITPD20060400A1 (it)	2008-05-01	"struttura di muffola"
FR2919553B1 (fr)	2009-10-23	Balai d'essuie-glace
ES1064510Y (es)	2007-06-16	Seguidor solar
FR2912204B3 (fr)	2010-06-18	Guirlande d'illumination
BRPI0906321A2 (pt)	2015-07-07	"multienzima"
BRPI0818848A2 (pt)	2015-04-14	Compostos de 2,3-di-idro-benzofurano